Together with published case reports, all identified anti-MDA5+/ARS+ DM cases received glucocorticoids and additional treatments, including CNI, IVCY, IVIG, tofacitinib, rituximab, plasmapheresis, and VV-ECMO. Here, IFIH1 is linked to dermatomyositis.